Try our Advanced Search for more refined results
November 30, 2009
Track this case
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood drug Neopogen until 2013.
Already a subscriber? Click here to login